Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) EBITDA Margin (2016 - 2025)

Iradimed (IRMD) has disclosed EBITDA Margin for 13 consecutive years, with 57.72% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 8763.0% to 57.72% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 7.11% through Dec 2025, down 2288.0% year-over-year, with the annual reading at 7.11% for FY2025, 2288.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 57.72% at Iradimed, down from 32.23% in the prior quarter.
  • The five-year high for EBITDA Margin was 35.78% in Q3 2023, with the low at 57.72% in Q4 2025.
  • Average EBITDA Margin over 5 years is 24.36%, with a median of 29.09% recorded in 2023.
  • The sharpest move saw EBITDA Margin skyrocketed 6191bps in 2021, then tumbled -8763bps in 2025.
  • Over 5 years, EBITDA Margin stood at 26.19% in 2021, then rose by 9bps to 28.62% in 2022, then grew by 3bps to 29.57% in 2023, then rose by 1bps to 29.92% in 2024, then crashed by -293bps to 57.72% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 57.72%, 32.23%, and 33.26% for Q4 2025, Q3 2025, and Q2 2025 respectively.